Edmonton, Alberta-based Nanostics Inc., which is developing a liquid biopsy platform for the early diagnosis of clinically significant prostate cancer, reported the start of its key clinical validation study. This study is part of the process towards meeting U.S. FDA and Health Canada requirements for an in vitro diagnostic test, allowing the Claritydx Prostate test to be provided to patients. The Claritydx Prostate test could help in the elimination of unnecessary biopsies and treatments, as well as lower health care costs. Read More
